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Objective: To compare the pattern of intraocular pressure (IOP) reduction following selective 
laser trabeculoplasty (SLT) versus argon laser trabeculoplasty (ALT) in open-angle glaucoma 
(OAG) patients, and to investigate the ability of initial IOP reduction to predict mid-term 
success.
Methods: A prospective, nonrandomized, interventional case series was carried out. Consecutive 
uncontrolled OAG glaucoma patients underwent SLT or ALT; the same preoperative medical 
regimen was maintained during follow-up. Data collected included age, type of OAG, pre- and 
postoperative IOP, number of glaucoma medications, and surgical complications. Post-treatment 
assessments were scheduled at day 1 and 7 and months 1, 3, and 6.
Results: A total of 45 patients (45 eyes) were enrolled [SLT group (n = 25); ALT group (n = 20)]. 
Groups were similar for age, baseline IOP, and number of glaucoma medications (P $ 0.12). 
We found no significant differences in mean IOP reduction between SLT (5.1 ± 2.5 mmHg; 
26.6%) and ALT (4.4 ± 2.8 mmHg; 22.8%) groups at month 6 (P = 0.38). Success rates 
(IOP # 16 mmHg and IOP reduction $25%) at last follow-up visit were similar for SLT (72%) 
and ALT (65%) groups (P = 0.36). Comparing the pattern of IOP reduction (% of IOP reduction 
at each visit) between groups, we found a greater effect following SLT compared with ALT at 
day 7 (23.7% ± 13.7% vs 8.1% ± 9.5%; P , 0.001). No significant differences were observed 
at other time points (P $ 0.32). Additionally, the percentage of IOP reduction at day 7 and at 
month 6 were significantly correlated in the SLT group (R2 = 0.36; P , 0.01), but not in the 
ALT group (P = 0.89). Early postoperative success predicted late success in most SLT cases 
(82%). No serious complications were observed.
Conclusion: Although mid-term results suggest SLT and ALT as effective and equivalent 
alternatives, a greater initial IOP reduction was observed following SLT. In addition, the 
initial IOP reduction was a good predictor of mid-term success in patients undergoing SLT, 
but not ALT.
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Introduction
Laser trabeculoplasty has become an important tool in the treatment of open-angle 
glaucoma (OAG). This procedure reduces intraocular pressure (IOP) by improving 
the facility of outflow. In 1979, Wise and Witer1 demonstrated that argon laser tra-
beculoplasty (ALT) was able to reduce IOP.1,2 They postulated that thermal energy 
produced by pigment absorption of laser light caused shrinkage of collagen in the 
trabecular lamellae and believed that the subsequent shortening of treated trabecular Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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meshwork (TM) might enlarge existing spaces between 2 
treatment sites or expand Schlemm’s canal by pulling the 
meshwork centrally. Traditionally, ALT has been performed 
using the blue-green, bichromatic wavelength spectrum 
(454.5 to 528.7 nm). As a main side effect, thermal damage 
induced by argon laser can lead to synechiae formation in 
the anterior chamber angle.3
More recently (1995), a frequency-doubled q-switched 
neodymium:yttrium–aluminum–garnet (Nd:Yag) laser was 
developed to lower IOP in patients with glaucoma by selec-
tively targeting the pigmented cells in the TM without caus-
ing thermal or collateral damage to nonpigmented cells or 
adjacent structures.4–7 Selective laser trabeculoplasty (SLT) 
delivers 80 to 100 times less energy than ALT, preserving 
the TM architecture in animal models, and it is potentially 
repeatable.8,9
Several studies have compare ALT with SLT, in terms of 
IOP reduction and medical dependency, showing equivalent 
short-term success.10–14 In this study, we sought to compare 
the pattern of IOP reduction (% of IOP reduction at each time 
point) following SLT versus ALT in treated OAG patients. 
In addition, we evaluated the ability of initial IOP reduction 
to predict mid-term success.
Methods
This prospective, nonrandomized, interventional study 
followed the tenets of the Declaration of Helsinki and was 
approved by the institutional review board. Written informed 
consent was obtained from all patients.
Patients
Patients included in this study were enrolled from 3 differ-
ent centers: the Glaucoma Unit of the Federal University of 
São Paulo, Hospital Medicina dos Olhos and CERPO. All 
patients had OAG with uncontrolled IOP (individualized for 
each patient, based on the level of glaucomatous damage) on 
maximal tolerated medical treatment and age .18 years.
Exclusion criteria were visual field defect within 10° 
of fixation, previous laser or incisional glaucoma surgery, 
corneal disease, history of steroid use, and any patient 
who required more than 25% of IOP reduction to reach   
target IOP.
Procedures
Data collected included age, type of OAG, preoperative 
and postoperative IOP, number of glaucoma medications, 
gonioscopy appearance, surgical complications, and any 
subsequent related events.
Both ALT and SLT were performed under   topical 
  anesthesia. In the SLT group a frequency-doubled 
Q-switched Nd:YAG laser (Laserex TangoTM Nd:YAG, Ellex 
Medical, Australia) emitting at 532 nm with pulse duration 
of 3 nanoseconds and a spot size of 400 µm coupled to a 
  slit-lamp delivery system. A Goldmann 3-mirror goniolens 
was placed on the eye with 1% methylcellulose. The aiming 
beam was focused onto the pigmented TM. The 400 µm spot 
size was large enough to irradiate the entire anteroposterior 
height of the TM. In all eyes, approximately 50 adjacent 
but nonoverlapping laser spots were placed over the infe-
rior 180° of the TM. Initial energy level was set to 0.80 mJ 
and changed according to the level of TM   pigmentation. 
The end point of each laser application was minibubble 
formation. In ALT group the patients were treated with a 
coherent argon laser with the blue-green (Ophthalas, Argon 
green laserTM, Alcon, Fort Worth, TX) biochromatic wave-
length spectrum (454.5 to 528.7 nm), with a 0.1-second 
pulse duration and a spot size of 50 µm coupled to a slit-
lamp delivery system. A Goldmann 3-mirror goniolens was 
placed on the eye with 1% methylcellulose. The aiming 
beam was focused onto the pigmented TM. Initial energy 
level was set to 400 mW and changed according to the level 
of TM pigmentation. The end point of each laser application 
was minibubble formation or focal tissue whitening. From 
400 to 1000 mW of energy was delivered. For comparison, 
1 Joule is equivalent to 1 Watt*second. Forty-five to 55 
adjacent nonoverlapping spots were applied to the inferior 
180° of the TM. Brimonidine 0.2% was instilled before 
and after the procedures, and 1% prednisolone acetate or 
0.1% dexamethasone acetate was administrated 4 times a 
day for 5 days.
All the procedures were done by the same (experienced) 
surgeon. Patients were maintained on the same antiglaucoma 
drugs before and after laser treatment. Post-treatment assess-
ments were scheduled at week 1 and months 1, 3, and 6. 
Visits occurred around the same time of day, whenever pos-
sible, to account for diurnal IOP fluctuation. Main outcomes 
were the pattern of IOP reduction (% of IOP reduction at 
each time point) following SLT versus ALT, and the abil-
ity of initial IOP reduction (day 7) to predict late success 
(month 6).
statistical analysis
Independent samples t-test was used to compare the magni-
tude of IOP reduction between groups. Regression analysis 
was used to correlate initial and late IOP reduction in each 
group. Frequency data were analyzed using chi-square test.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Results
A total of 45 consecutive patients were enrolled, 25 patients 
in SLT group (25 eyes) and 20 patients in the ALT group 
(20 eyes). Most patients had primary OAG (86%). Groups 
were similar for age, gender, race, mean preoperative IOP, and 
number of glaucoma medications (P $ 0.09).   Pretreatment 
demographic and clinical characteristics of study patients 
are provided in Table 1.
We found no significant difference in mean IOP reduc-
tion between SLT (5.1 ± 2.5 mmHg; 26.6%) and ALT 
(4.4 ± 2.8 mmHg; 22.8%) groups at 6 months (P = 0.38). Success 
rates (defined as IOP # 16 mmHg and IOP reduction $25%) at 
last follow-up visit were also similar for SLT (72%) and ALT 
(65%) groups (P = 0.36). Comparing the IOP reduction pat-
tern (% of IOP reduction at each time point; Figures 1 and 2) 
between groups, we found a greater IOP reduction follow-
ing SLT compared with ALT at day 7 (23.7% ± 13.7% vs 
8.1% ± 9.5%; P , 0.001). No significant differences were 
observed at the other time points (P $ 0.32).
The percentage of initial IOP reduction at (day 7) cor-
related significantly with IOP reduction at month 6 in the 
SLT group (R2 = 0.36; P , 0.01), but not in the ALT group 
(P = 0.89). In addition, early postoperative success (at day 7) 
predicted late success (at month 6) in most cases treated with 
SLT (82%), but only in 29% of those treated with ALT.
Finally, 1 patient developed sustained IOP rise ($10% 
IOP increase in 2 consecutive visits) in each group. The 
patient from the ALT group was relatively young and had 
significant visual field damage. Consequently, he was later 
submitted to a trabeculectomy with mitomycin-C. After the 
last follow-up visit, IOP values were close to baseline IOP 
in the patient from the SLT group. This patient is currently 
being followed. No cases of peripheral synechiae develop-
ment or other serious complications were observed.
Discussion
Both ALT and SLT are procedures frequently used in 
OAG treatment. Most previously published studies focused 
  primarily on the magnitude of IOP reduction, and reported 
similar results for the two treatment modalities. As far as we 
know, this is the first study to compare the pattern of IOP 
reduction between ALT and SLT, and to report on the ability 
of initial IOP reduction to predict mid-term success.
In this study, comparing the IOP-lowering efficacy of 
ALT and SLT in treated OAG patients, we found no sig-
nificant difference between groups after 6 months. Our 
results are in agreement with previously published data. 
Damji et al found similar results at 6 months evaluating a 
sample of 36 eyes.12 A prospective study by Hollo,15 in which   
patients underwent ALT in 1 eye and SLT in the fellow eye, 
found equivalent outcomes. Another prospective study by 
Martinez-de-la-Casa et al9 treated consecutive patients with 
SLT (20 eyes) and ALT (20 eyes). After 6 months, a similar 
Table 1 Clinical characteristics of study patients
SLT (n = 25) ALT (n = 20) P 
Age (years) 62.4 ± 13.8 63.8 ± 12.5 0.74
gender (M/F) 6/19 5/15 0.87
race (W/B/A/M) 
Preoperative iOP (mmhg)
15/4/3/3 
19.2 ± 2.3
9/5/1/5 
20.5 ± 2.9
0.09 
0.12
glaucoma medications 2.3 ± 0.8 2.5 ± 0.7 0.71
Note: *Data are given as mean ± standard deviation whenever indicated.
Abbeviations: ALT, argon laser trabeculoplasty; sLT, selective laser trabeculoplasty; 
iOP, intraocular pressure; M, male; F, female; W, White; B, Black; A, Asian; M, mixed.
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Figure 1 intraocular pressure values (mmhg) at each time point. Comparison 
between argon laser trabeculoplasty (ALT) and selective laser trabeculoplasty (sLT) 
groups.
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Figure 2 Percentage of intraocular pressure (iOP) reduction at each time point. 
Comparison  between  argon  laser  trabeculoplasty  (ALT)  and  selective  laser 
trabeculoplasty (sLT) groups. Means and error bars (95% Ci) are provided.Clinical Ophthalmology
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reduction in IOP was observed. Finally, in a larger series 
(176 eyes), Damji et al16 reported equivalent success rates 
(IOP reduction $20%) between treatments after 6 months.
The main outcome measurement of our study was the 
analysis of the pattern of IOP reduction. There are no previ-
ously published data on this topic. Comparing the magnitude 
of IOP reduction at each time point following laser treatment, 
initial IOP reduction (day 7) was greater in the SLT group. 
In addition, this initial outcome was a significant predictor of 
mid-term success for these patients, but not for those treated 
with ALT. One could hypothesize that this difference could 
be related to the specific action of the selective laser in the 
pigmented cells of the TM. While SLT stimulates aqueous 
outflow without structural damage to the TM, ALT firstly 
requires structural damage and subsequent tissue healing to 
increase outflow facility, which may need a longer period to 
occur.1,7,17 Our findings suggest that SLT seems to be a better 
option in patients requiring a faster IOP reduction following 
laser trabeculoplasty.
There are some specific characteristics of our study that 
should be considered while interpreting its findings. First, 
although prospective, it was not randomized. Second, its 
sample size was limited. A larger sample might have revealed 
different outcomes. Finally, a study with a longer follow-up 
is warranted in order to confirm the pattern of IOP reduction 
we found for each laser modality.
Conclusion
In summary, these mid-term results suggest SLT and ALT as 
safe, effective, and equivalent alternatives for IOP reduction 
in treated OAG patients. A greater initial (first week) IOP-
lowering effect was observed following SLT. In addition, 
the initial IOP reduction was a good predictor of mid-term 
success in patients undergoing SLT, but not ALT. These 
findings add to our previous knowledge on laser treatment, 
and should be considered while indicating and following 
patients undergoing laser trabeculoplasty.
Disclosure
None of the authors have any commercial interest regarding 
the present study.
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